

SUNDAY JUNE 26th, 2022	
05:00 PM – 06:00 PM	Registration
06:00 PM – 09:00 PM	Opening Session and Reception

MONDAY JUNE 27th, 2022	
Epidemiology and Clinical Aspects of Pertussis	
Session Chairs: Nicky Klein and Scott Halperin.	

08:30 AM - 09:00 AM	Bernice Aronsson. Pertussis vaccine studies in Sweden
09:00 AM - 09:15 AM	Fahima Moosa. Incidence and transmission dynamics of Bordetella pertussis in an urban and rural community in South Africa, PHIRST study, 2016-2018
09:15 AM - 09:30 AM	Anja Saso. Vaccine-induced antibody responses to pertussis detected in the upper airway of Gambian infants
09:30 AM - 09:45 AM	Lingzi Xiaoli. Molecular characterization of seven Bordetella pertussis strains from Brazil with suspected pertactin deficiency
09:45 AM - 10:00 AM	Michael Weigand. Integrating genomics into enhanced surveillance of Bordetella pertussis in the United States, 2010–2020
10:00 AM - 10:30 AM	Morning Break

Pertussis Immunity and Vaccinology I	
Session Chairs: Heath Damron and Kingston Mills.	

10:30 AM - 11:00 AM	Dimitri Diavatopoulos. Early induction of mucosal type 2 immunity and T-cells is associated with enhanced control of Bordetella pertussis infection in humans.
11:00 AM - 11:15 AM	Andrew Gorringe. A comparison of anti-Bordetella pertussis bactericidal antibody responses to natural infection, acellular, whole cell and live attenuated pertussis vaccines
11:15 AM - 11:30 AM	Megan DeJong. Utilizing the CpG 1018 adjuvant to improve immune responses to Tdap
11:30 AM - 11:45 AM	David Dowling. Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination
11:45 AM - 12:00 PM	Pablo Martin Aispuro. Bordetella pertussis responses in neonates mice born to animals primed with whole-cell versus acellular vaccine in infancy
12:00 PM - 12:30 PM	Lunch

A dynamical model to illustrate the possible evolution of B. pertussis toward a lower virulence under acellular vaccination

Florian Lecorvaisier

Protection by Bordetella pertussis against influenza: role of pertussis toxin

Stephane Cauchi

Eosinophils and inflammation, the untold story

Monica Cartelle Gestal

Identification of residues involved in posttranslational modification of RTX toxins of Gram-negative pathogens

Michaela Grobarcikova

Impact of the COVID-19 pandemic on Bordetella pertussis infections in England

Elise Tessier

Characteristics of Pertussis-related Deaths Reported in the United States, 2012–2020

Tami Skoff

Validation of culture-independent whole genome sequencing pipeline for Bordetella pertussis

Yanhui Peng

Pertussis toxin suppresses dendritic cell-mediated delivery of B. pertussis into lung-draining lymph nodes

Nela Klímová

Comparison of aP or wP vaccines and primo-exposure against Bordetella pertussis in baboon model

Mathilde Galhaut

Agreement between two Commercial Laboratories and CDC's RT-PCR assays in Identification of Bordetella pertussis in the United States

Marissa Fraire

Outer membrane vesicle based vaccine used in an heterologous prime-boost scheme prevent Bordetella pertussis nasal mice colonization

Erika Rudi

Innate immune response during the catarrhal phase of the pertussis disease

Ludmila Brázdilová

Comparative Phosphoproteomics of Classical Bordetellae Elucidates the Potential Role of Serine, Threonine and Tyrosine Phosphorylation in Bordetella Biology and Virulence

Laurence Don Wai Luu

Effects of acellular pertussis vaccination on nasal Bordetella pertussis carriage

Violaine Dubois

Assessing the Impact of the Modified Council of State and Territorial Epidemiologists Case Definition for Pertussis on Reported Pertussis, 2020

Amy Blain

Analysis of pertussis cases in England from 2013- 2016 reveals an increase in circulating pertactin-deficient isolates but no increase in disease severity

Elise Tessier

New Model of Persistent Neonatal-like Immunity Reveals Increased Susceptibility to Bordetella pertussis

Colleen Sedney

Comparison of US macrolide resistant Bordetella pertussis with those reported worldwide

Pamela K. Cassidy

Rapid Screening and Characterization of Vaccine Immunogen-deficiency in clinical Bordetella pertussis isolates, 2012–2020

Hong Ju

The Response Regulator RisR Prevents Toxic Overexpression of vrgs in the Bordetella pertussis Bvg--mode

Qing Chen

Targeting essential Bordetella pertussis functions to prevent colonization, disease, and transmission

Timothy Brickman

Determining the structural features of Bordetella LPS that influence TLR4 recognition and subsequent NFkB signalling

Kiruthika Manivannan

pIG25: A tetracycline-inducible gene expression system for Bordetella spp.

Gyles Ifill

Bordetella pertussis-induced IDO responses are age-dependent and potentiate severe disease

Karen Scanlon

Pathogenesis and Biology of Bordetellae I

Session Chairs: Ruiting Lan and Karen Scanlon

02:00 PM - 02:30 PM	Scott Stibitz. RisR – a phantom presence in vrg-regulation.
02:30 PM - 02:45 PM	Loic Coutte. Integrative analyses of the direct and indirect RisA regulon of Bordetella pertussis
02:45 PM - 03:00 PM	Nicholas First. Disruption of the VIP/VPAC2 Axis Limits Colonization and Enhances Clearance of Bordetella spp. from the Lower Respiratory Tract
03:00 PM - 03:15 PM	Audra Fullen. The Bordetella polysaccharide Bps resists antimicrobial peptides and converts Escherichia coli into a respiratory pathogen
03:15 PM - 03:30 PM	Jana Holubova. The Fim and FhaB adhesins play a crucial role in nasal cavity infection and Bordetella pertussis transmission in a novel mouse catarrhal infection model
03:30 PM – 03:45 PM	Afternoon Break
03:45 PM - 04:00 PM	David Rickert. Peptidoglycan recognition proteins mediate the balance between protective and pathogenic responses to Bordetella pertussis
04:00 PM - 04:15 PM	David McCulloch. Investigating fundamental differences in the essentiality of B. pertussis cell wall biosynthesis genes.
04:15 PM - 04:30 PM	Hiroki Suyama. Integrating proteomic data with metabolic modelling provides insight into key pathways in Bordetella pertussis biofilms
04:30 PM - 04:45 PM	Yukihiro Hiramatsu. The mechanism of pertussis cough revealed by the mouse-coughing model

04:45 PM - 06:30 PM In-Person Poster Session

TUESDAY JUNE 28th, 2022

Pertussis Immunity and Vaccinology II

Session Chairs: Tod Merkel and Dimitri Diavatopoulos.

08:30 AM - 09:00 AM	Kingston Mills. The mechanism of protective immunity against nasal infection with Bordetella pertussis – the key to the design of an improved pertussis vaccine.
---------------------	---

09:00 AM - 09:15 AM	Ricardo da Silva Antunes. Genome-wide characterization of T cell responses to Bordetella pertussis reveals broad reactivity and defines novel targets for next-generation vaccines
09:15 AM - 09:30 AM	Yihui Wang. “Original Antigenic Sin” in Humoral Responses to Acellular Pertussis Vaccination in the Baboon Model
09:30 AM - 09:45 AM	Hans de Graaf. Bordetella pertussis colonization can be safely induced in an outpatient setting and induces protective immunity against re-challenge
09:45 AM - 10:00 AM	May ElSherif. Establishing a Controlled Human Infection Model of Bordetella pertussis in North America
10:00 AM - 10:15 AM	Lucia Pawloski. Establishing a Pertussis Controlled Human Infection Model Biorepository: Providing support for future vaccinology research

10:15 AM - 10:45 AM Morning Break

Pathogenesis and Biology of Bordetellae II

Session Chairs: Sandy Armstrong and Camille Locht.

10:45 AM - 11:15 AM	Francoise Jacob-Dubuisson. Copper homeostasis in Bordetella pertussis: how a host-restricted pathogen deals with copper
11:15 AM - 11:30 AM	Gauthier Roy. Post-transcriptional regulation by copper with a new upstream Open Reading Frame
11:30 AM - 11:45 AM	Deborah Hinton. Characterization of a Bordetella pertussis sRNA whose expression regulates a sigma54 transcriptional regulator, an ABC transporter operon, and the gene for a 3-hydroxyisobutyrate dehydrogenase
11:45 AM - 12:00 PM	Kristin Surmann. The impact of BP1092 on Bordetella pertussis virulence factor regulation
12:00 PM - 12:15 PM	Sherlene Brown. Discovery and Characterization of a Fic Protein from Bordetella Bronchiseptica with Guanylyltransferase Activity
12:15 PM - 12:30 PM	Xiujun Li. Rapid and Accurate Diagnosis of Pertussis on a Point-of-Care Biochip

12:30 PM - 01:00 PM International Bordetella Society Townhall

1:00 PM - 01:30 PM Lunch. Boxed lunch to go.

01:30 PM Free afternoon to network and explore

WEDNESDAY JUNE 29th, 2022

Pathogenesis and Biology of Bordetellae III

Session Chairs: Maria Rodriguez and Erik Hewlett.

08:30 AM - 09:00 AM	Branislav Vecerek. Adaptation of Bordetella pertussis to intramacrophage environment
09:00 AM - 09:15 AM	Carlos Baroli. Bordetella parapertussis adenylate cyclase toxin grants the bacterial invasion of and persistence within respiratory epithelial cells
09:15 AM - 09:30 AM	Guojun Chen. Templated Folding of the RTX Domain of the Bacterial Toxin Adenylate Cyclase Revealed by Single Molecule Force Spectroscopy
09:30 AM - 09:45 AM	Alexa R. Spandrio. A Juggling ACT: Distinct adenylate cyclase toxin functions during Bordetella persistence in vivo
09:45 AM - 10:00 AM	Dzifa Amengor. Antibodies neutralizing the adenylate cyclase toxin synergize with opsonizing antibodies to protect mice against B. pertussis
10:00 AM - 10:30 AM	Morning Break

Pertussis Immunity and Vaccinology III

Session Chairs: Marcela Pasetti and Manish Sadarangani.

10:30 AM - 11:00 AM	Bahaa Abu Raya. Immune responses to vaccination against pertussis in pregnancy in mother-infants dyad.
11:00 AM - 11:30 AM	Kirsten Maertens. Maternal vaccination for pertussis.
11:30 AM - 11:45 AM	Purnima Dubey. Characterizing the cellular and humoral immune responses to Tdap during pregnancy compared to non-pregnant controls
11:45 AM - 12:00 PM	Susana Portillo. Longitudinal analysis of pertussis antibodies in maternal sera and breast milk using a high throughput multiplex MSD assay
12:00 PM - 12:30 PM	Lunch

12:30 PM – 01:15 PM Virtual Poster Session III

The safety of a combined pertussis containing vaccine for pregnant women living with HIV and their infants - a randomized controlled trial in Uganda

Eve Nakabembe

Bordetella spp. blocks eosinophil trap formation to suppress eosinophilbactericidal activity

Connor Roan

Disruption of btrS-mediated immunomodulation results in enhanced nasal cavity and pulmonary immune responses to Bordetella pertussis.

Amanda Caulfield

CyaA delivered by B. pertussis OMVs dampens human neutrophils protective function

Maria Eugenia Rodriguez

B cell epitope peptide conjugates as B. pertussis vaccine antigens

Gage Pyles

BPZE1 LIVE ATTENUATED INTRANASAL PERTUSSIS VACCINE INDUCES BROAD FUNCTIONAL ANTIBODY RESPONSES

Peter Goldstein

Genetic Platform for the Isolation of Constitutive Mutations of the BvgS Sensor Kinase in Bordetella pertussis

Jordan Pardoe

The Bordetella T3SS uses multiple strategies to subvert innate and adaptive immunity

Margaret R. Dedloff

Bordetella pertussis booster vaccine responses in pregnant women primed with whole-cell vaccine

Eugenia Zurita

The impact of Tdap vaccination in successive pregnancies

Louise De Weerd

Identification of novel Bordetella pertussis antigens for next-generation pertussis vaccines

Nicole Lamond

MOLECULAR IDENTIFICATION OF BORDETELLA PERTUSSIS AND EXPRESSION OF ANTIGENS

Georgeta Cristina Oprea

01:15 PM – 2:00 PM

Virtual Poster Session IV

Genome-based prediction of cross-protective, CD4 T cell-inducing epitope targets as putative vaccine antigens for multiple Bordetella species

Muktha Natrajan

Evaluating nasal and muscular acellular pertussis vaccines containing a TLR4 agonist adjuvant

Megan DeJong

Characterization of emerging clinical isolates of Bordetella pertussis through omics and murine challenge models

Graham Bitzer

Age-dependent deficits in interferon-gamma and natural killer cells contribute to severe Bordetella pertussis in infant mice

Ashley Mitchell

MIDDLE EAR INFECTIONS WITH THE BORDETELLAE

Kalyan Dewan

Epidemiologic Characteristics and Trends of Bordetella bronchiseptica Identified through Enhanced Pertussis Surveillance, United States, 2011–2020

Matthew Cole

A novel and versatile immune assay to evaluate vaccination and infection-induced antibody-mediated recognition of Bordetella pertussis

Janeri Fröberg

Analysis of serum bactericidal activity in sera from OPTIMUM: A randomised control trial investigating the timing of pertussis vaccination in pregnancy.

Rachel Halkerston

DIGUANYLATE CYCLASE BdcB INHIBITS TYPE THREE SECRETION SYSTEM IN B. BRONCHISEPTICA AND IMPACTS ON IMMUNE RESPONSE

Keila Belhart

Heterologous expression of the Bordetella pertussis LgmB membrane protein in Rhodobacter sphaeroides results in high yields suitable for structural and biophysical characterization

Amita Mahey

Development of a sensitive transmission model of Bordetella bronchiseptica

Yang Su

Bordetella Genome Analyses

Session Chairs: Rachel Fernandez and Eric Harvill.

02:00 PM - 2:15 PM

Eric Harvill. Ecology and Evolution of the Bordetella species

02:15 PM - 02:30 PM	Valérie Bouchez. Genomic library of Bordetella
02:30 PM - 02:45 PM	Noemie Lefrancq. Estimating global spatial dynamics and vaccine induced fitness changes of Bordetella pertussis
02:45 PM - 03:00 PM	Yi Ling Tam. Building a k-mer based GWAS pipeline to identify genome rearrangement associations in Bordetella pertussis
03:00 PM - 03:15 PM	Laurence Don Wai Luu. Genomic dissection of the microevolution of Australian epidemic Bordetella pertussis
03:15 PM - 03:30 PM	Michael Payne. A flexible and standardised multilevel genome typing (MGT) scheme for Bordetella pertussis
03:30 PM - 3:45 PM	Afternoon break

Pertussis Immunity and Vaccinology IV

Session Chairs: Kathy Edwards and Monica Cartelle Gestal.

03:45 PM - 4:15 PM	Camille Locht. Live attenuated pertussis vaccine: on- and off-target effects
04:15 PM - 04:30 PM	C. Buddy Creech. Safety and Immunogenicity of Live, Attenuated Intranasal Bordetella pertussis Vaccine (BPZE1) in Healthy Adults
04:30 PM - 04:45 PM	Stephanie Noviello. BPZE1, AN INTRANASAL LIVE ATTENUATED PERTUSSIS VACCINE, EVALUATED IN HEALTHY ADULTS: A PHASE 2B, MULTI-CENTER, PLACEBO-CONTROLLED, RANDOMIZED STUDY

06:30 PM - 10:00 PM Banquet at Sage Bistro 6331 Crescent Rd, Vancouver, BC V6T 1Z1

THURSDAY JUNE 30th, 2022

Pertussis Immunity and Vaccinology V

Session Chairs: Peter Sebo and Daniela Hozbor.

08:30 AM - 09:00 AM	F. Heath Damron. mRNA vaccines for pertussis
09:00 AM - 09:15 AM	Mohamed Shamseldin. An unbiased biochemical approach to identify novel CD4+ T cell recognized antigens from B. pertussis
09:15 AM - 09:30 AM	Caitlín Ní Chasaide. Vaccine Approaches for Promoting Local Immunity and Memory to Bordetella pertussis in the Nasal Mucosa
09:30 AM - 09:45 AM	Kelly Weaver. Characterization of acellular pertussis vaccine-induced memory responses and improvement of responses by use of novel adjuvants

09:45 AM - 10:00 AM	Da'Kuawn Johnson. Effects of Type III IFN Signaling in Neonatal Bordetella Pertussis Infection and Disease
10:00 AM - 10:15 AM	Break
10:15 AM - 10:45 AM	Jennifer Maynard. Using antibodies to define the contributions of B. pertussis virulence factors to protection
10:45 AM - 11:45 AM	Roundtable Discussion. Current challenges and future directions
11:45 AM - 12:00 PM	Lunch. To go lunch.